This article was originally published on ETFTrends.com. AXS Investments today announced the launch of the AXS Brendan Wood TopGun Index ETF (NYSE Arca: TGN). TGN seeks to track the Brendan Wood TopGun ...
— Enrollment completed in the study with no serious adverse events considered related to TGN-S11 in participants who received monotherapy in completed Part 1 and who received TGN-S11 in combination ...
US-based biotechnology company Toragen has reported positive safety outcomes from a Phase I trial of TGN-S11, its small molecule drug candidate for the treatment of human papillomavirus (HPV) related ...
Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the iShares MSCI Emerging Markets ETF, where 24,750,000 units ...
SAN DIEGO--(BUSINESS WIRE)--Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results